1. Keep MF, Uchino H, Elmér E. Immunosuppressants as neuroprotective
agents. In: Borlongan C, Sanberg P, Isacsson O, editors. Immunosuppressants
and neurological disorders: Humana Press, 2002
2. Bart J, Groen HJ, Hendrikse NH, van der Graaf WT, Vaalburg W, de
Vries EG. The
blood-brain barrier and oncology: new insights into function and modulation.
Cancer Treat Rev 2000;26(6):449-462.
3. Morioka M, Hamada J, Ushio Y, Miyamoto E. Potential
role of calcineurin for brain ischemia and traumatic injury. Prog
Neurobiol 1999;58(1):1-30.
4. Siesjo BK, Elmer E, Janelidze S, Keep M, Kristian T, Ouyang YB and
Uchino H. Role
and mechanisms of secondary mitochondrial failure. Acta Neurochir
Suppl (Wien) 1999;73(6):7-13.
5. Bernardi P, Colonna R, Costantini P, Eriksson O, Fontaine E, Ichas
F, et al. The
mitochondrial permeability transition. Biofactors 1998;8(3-4):273-81.
6. Di Lisa F, Bernardi P. Mitochondrial
function as a determinant of recovery or death in cell response to injury.
Mol Cell Biochem 1998;184(1-2):379-91.
7. Kristian T, Siesjo BK. Calcium
in ischemic cell death. Stroke 1998;29(3):705-18.
8. Snyder SH, Sabatini DM, Lai MM, Steiner JP, Hamilton GS, Suzdak PD.
Neural
actions of immunophilin ligands. Trends Pharmacol. Sci. 1998;19(1):21-6.
9. Gold BG. FK506
and the role of immunophilins in nerve regeneration. Mol. Neurobiol.
1997;15(3):285-306.
10. Sabatini DM, Lai MM, Snyder SH. Neural
roles of immunophilins and their ligands. Mol Neurobiol 1997;15(2):223-39.
11. Bernardi P. The
permeability transition pore. Control points of a cyclosporin A- sensitive
mitochondrial channel involved in cell death. Biochim Biophys
Acta 1996;1275(1-2):5-9.
12. Siesjo BK, Siesjo P. Mechanisms
of secondary brain injury. Eur J Anaesthesiol 1996;13(3):247-68.
13. Fahr A. Cyclosporin
clinical pharmacokinetics. Clin Pharmacokinet 1993;24(6):472-95.
14. Akagi H, Reynolds A, Hjelm M. Cyclosporin
A and its metabolites, distribution in blood and tissues. J Int
Med Res 1991;19(1):1-18.
